DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Social Phobia

Intervention: Paroxetine (Drug)

Phase: N/A

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Summary

The study is designed to evaluate the safety and efficacy of paroxetine on the long-term use in Japanese Social Anxiety Disorder (SAD) subjects.

Clinical Details

Official title: Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)

Study design: N/A

Primary outcome: The number of adverse events in Japanese subjects with social anxiety disorder treated with paroxetine tablets

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects who are diagnosed as having SAD

- Subjects who are expected to use paroxetine tablets for the first time

Exclusion Criteria:

- Subjects taking pimozide

- Subjects taking monoamine oxidase (MAO) inhibitor or within two weeks after

discontinuation of MAO inhibitor

- Subjects with hypersensitivity to paroxetine

Locations and Contacts

Additional Information

Starting date: January 2010
Last updated: June 30, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017